fluconazole has been researched along with Fever in 38 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 9.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 9.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 9.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 9.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 7.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 5.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "A total of 317 neutropenic patients (<500 cells/mm3) with persistent or recrudescent fever despite 4 or more days of antibacterial therapy were randomly assigned to receive either fluconazole (400 mg intravenously once daily) or amphotericin B (0." | 5.09 | A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. ( Hathorn, JW; Schiller, GJ; Schuster, MG; Territo, MC; Winston, DJ, 2000) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 5.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 5.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 5.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| " Our study was designed to assess the prevention of (1) staphylococcal and streptococcal infections using T when the central catheter is being placed, and (2) candida infection by the simultaneous use of a new anti-mycotic agent fluconazole (F) administered once-daily." | 5.06 | Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children. ( Arlet, G; Baruchel, A; Schaison, G, 1990) |
| " A second opinion at our institute resulted in the diagnosis of hepatic candidiasis without prior documented candidemia, for which she was treated successfully with fluconazole." | 3.85 | Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis? ( Bomers, MK; de Rooij, ML; Meijer, E; Menke-van der Houven van Oordt, CW; van Dijk, K; van Prehn, J, 2017) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 3.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| " We encountered a tuboovarian abscess caused by Candida glabrata after chemotherapy with an anticancer drug, methotrexate, in a febrile neutropenic patient." | 3.72 | Tuboovarian abscess caused by Candida glabrata in a febrile neutropenic patient. ( Mikamo, H; Ninomiya, M; Tamaya, T, 2003) |
| "Fluconazole, a novel triazole antifungal agent, was given orally or intravenously to 10 patients with pulmonary mycosis (7 patients with primary pulmonary cryptococcosis and 3 with pulmonary aspergillosis)." | 3.67 | [Clinical efficacy of fluconazole in the patient with pulmonary mycosis]. ( Hanawa, T; Hatakenaka, R; Ikeda, S; Katsura, A; Kosaba, S; Lee, Y; Matsubara, Y; Ninomiya, K; Shiota, T; Yagi, K, 1989) |
| "Amphotericin B was significantly more toxic than Fluconazole especially in related allogeneic transplantation where 19% of patients developed toxicity vs 0% of Fluconazole recipients (p < 0." | 2.69 | Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. ( Bolwell, B; Collins, R; Dummer, S; Ericson, S; Fay, J; Freytes, CO; Goodman, SA; Greer, J; Herzig, RH; LeMaistre, F; Lynch, J; Pineiro, L; Pohlman, B; Stein, R; Stevens, D; Wolff, SN, 2000) |
| "Fungal infections are a major problem in patients with hematologic malignancy." | 2.68 | Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995) |
| "Fluconazole was the initial, antifungal agent used." | 1.43 | Coccidioidomycosis in infants: A retrospective case series. ( Dabrowski, L; Graciano, AL; Kuzmic, B; Lee, JM; Tablizo, MA, 2016) |
| "Our unique case presentation illustrates subcorneal pustular dermatosis as a reactive eruption owing to primary pulmonary coccidioidomycosis." | 1.42 | Subcorneal pustular dermatosis associated with Coccidioides immitis. ( Chambers, CJ; Chang, S; Fung, MA; Iyengar, S; Sharon, VR, 2015) |
| "Coccidioidomycosis is an insidious fungal disease, endemic to arid regions of the Americas, which is becoming more frequently recognised worldwide." | 1.40 | Beyond the superficial: Coccidioides immitis fungaemia in a man with fever, fatigue and skin nodules: a case of an emerging and evolving pathogen. ( Baxi, SM; Chin-Hong, P; Iribarne, D; Langelier, C, 2014) |
| " We compared patients who received 50 mg of caspofungin per day in a double-blind trial that used fluconazole as the comparator with patients who received the corresponding dosage in 2 similar earlier studies that used amphotericin as the comparator." | 1.35 | Double-blind active-control trials: beware the comparator you keep. ( Dinubile, MJ, 2008) |
| "Disseminated candidiasis is difficult to diagnose and treat, and often becomes life-threatening in critically ill patients." | 1.31 | Use of antifungal agents in febrile patients nonresponsive to antibacterial treatment: the current status in surgical and critical care patients in Japan. ( Aikawa, N; Hirasawa, H; Kusachi, S; Oda, S; Sumiyama, Y; Yamazaki, Y, 2002) |
| "There are few reports on cryptococcal meningitis in non-HIV-infected patients in subtropical areas." | 1.31 | Cryptococcal meningitis in non-HIV-infected patients. ( Chang, SC; Chen, YC; Hsieh, WC; Luh, KT; Shih, CC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 10 (26.32) | 18.2507 |
| 2000's | 18 (47.37) | 29.6817 |
| 2010's | 8 (21.05) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Azeem, A | 1 |
| Quimby, D | 1 |
| Krajicek, B | 1 |
| Horne, J | 1 |
| van Prehn, J | 1 |
| Menke-van der Houven van Oordt, CW | 1 |
| de Rooij, ML | 1 |
| Meijer, E | 1 |
| Bomers, MK | 1 |
| van Dijk, K | 1 |
| Shu, S | 1 |
| Xu, S | 1 |
| Wang, Y | 1 |
| Ye, F | 1 |
| Zhou, H | 1 |
| Fang, F | 1 |
| Langelier, C | 1 |
| Baxi, SM | 1 |
| Iribarne, D | 1 |
| Chin-Hong, P | 1 |
| Iyengar, S | 1 |
| Chambers, CJ | 1 |
| Chang, S | 1 |
| Fung, MA | 1 |
| Sharon, VR | 1 |
| Lee, JM | 1 |
| Graciano, AL | 1 |
| Dabrowski, L | 1 |
| Kuzmic, B | 1 |
| Tablizo, MA | 1 |
| Dinubile, MJ | 1 |
| Sobrevilla Calvo, P | 1 |
| Hamoud, S | 1 |
| Keidar, Z | 1 |
| Hayek, T | 1 |
| Beam, E | 1 |
| Mansfield, AS | 1 |
| Thompson, CA | 1 |
| Tascini, C | 1 |
| Ferranti, S | 1 |
| Gemignani, G | 1 |
| Messina, F | 1 |
| Menichetti, F | 2 |
| Aikawa, N | 1 |
| Sumiyama, Y | 1 |
| Kusachi, S | 1 |
| Hirasawa, H | 1 |
| Oda, S | 1 |
| Yamazaki, Y | 1 |
| Alvarez-Lerma, F | 1 |
| Nolla, J | 1 |
| Palomar, M | 1 |
| León, MA | 1 |
| Mikamo, H | 1 |
| Ninomiya, M | 1 |
| Tamaya, T | 1 |
| Kolbin, AS | 1 |
| Klimko, NN | 1 |
| Karpov, OI | 1 |
| Pietrobon, D | 1 |
| Negro-Marquínez, L | 1 |
| Kilstein, J | 1 |
| Galíndez, J | 1 |
| Greca, A | 1 |
| Battagliotti, C | 1 |
| Wingard, JR | 1 |
| Stemmer, SM | 1 |
| Maor, Y | 1 |
| Hardan, I | 1 |
| Long, JB | 1 |
| Brett, AS | 1 |
| Horvath, JA | 1 |
| Yu, DT | 1 |
| Seger, DL | 1 |
| Peterson, JF | 1 |
| Kumar, RN | 1 |
| Bates, DW | 1 |
| Hanninen, M | 1 |
| Dean, N | 1 |
| Schaffner, A | 1 |
| Schaffner, M | 1 |
| Ellis, ME | 1 |
| Halim, MA | 1 |
| Spence, D | 1 |
| Ernst, P | 1 |
| Clink, H | 1 |
| Kalin, M | 1 |
| Baillie, F | 1 |
| Greer, W | 1 |
| Chubachi, A | 2 |
| Miura, I | 2 |
| Ohshima, A | 2 |
| Nishinari, T | 1 |
| Nimura, T | 2 |
| Niitsu, H | 2 |
| Miura, AB | 2 |
| Broun, ER | 1 |
| Wheat, JL | 1 |
| Kneebone, PH | 1 |
| Sundblad, K | 1 |
| Hromas, RA | 1 |
| Tricot, G | 1 |
| Ong, ST | 1 |
| Kueh, YK | 1 |
| Viscoli, C | 1 |
| Castagnola, E | 1 |
| Van Lint, MT | 1 |
| Moroni, C | 1 |
| Garaventa, A | 1 |
| Rossi, MR | 1 |
| Fanci, R | 1 |
| Caselli, D | 1 |
| Giacchino, M | 1 |
| Congiu, M | 1 |
| Malik, IA | 1 |
| Moid, I | 1 |
| Aziz, Z | 1 |
| Khan, S | 1 |
| Suleman, M | 1 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Olivieri, A | 1 |
| Rupoli, S | 1 |
| Frayfer, J | 1 |
| Mele, A | 1 |
| Manso, E | 1 |
| Montanari, M | 1 |
| Centurioni, R | 1 |
| Leoni, P | 1 |
| Shih, CC | 1 |
| Chen, YC | 1 |
| Chang, SC | 1 |
| Luh, KT | 1 |
| Hsieh, WC | 1 |
| Wolff, SN | 1 |
| Fay, J | 1 |
| Stevens, D | 1 |
| Herzig, RH | 1 |
| Pohlman, B | 1 |
| Bolwell, B | 1 |
| Lynch, J | 1 |
| Ericson, S | 1 |
| Freytes, CO | 1 |
| LeMaistre, F | 1 |
| Collins, R | 1 |
| Pineiro, L | 1 |
| Greer, J | 1 |
| Stein, R | 1 |
| Goodman, SA | 1 |
| Dummer, S | 1 |
| Winston, DJ | 1 |
| Hathorn, JW | 1 |
| Schuster, MG | 1 |
| Schiller, GJ | 1 |
| Territo, MC | 1 |
| Bodey, GP | 1 |
| Chandrasekar, PH | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Choi, JH | 1 |
| Yoo, JH | 1 |
| Park, YH | 1 |
| Kim, YJ | 1 |
| Lee, S | 1 |
| Min, CK | 1 |
| Kim, HJ | 1 |
| Kim, DW | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Shin, WS | 1 |
| Kim, CC | 1 |
| Schaison, G | 1 |
| Baruchel, A | 1 |
| Arlet, G | 1 |
| Lee, Y | 1 |
| Shiota, T | 1 |
| Ikeda, S | 1 |
| Katsura, A | 1 |
| Hanawa, T | 1 |
| Yagi, K | 1 |
| Kosaba, S | 1 |
| Hatakenaka, R | 1 |
| Matsubara, Y | 1 |
| Ninomiya, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis[NCT00723073] | 323 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 10 |
| Micafungin Arm | 9 |
Median number of days patients were hospitalized during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 29 |
| Micafungin Arm | 28 |
Median number of days patients were neutropenic during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 20 |
| Micafungin Arm | 17 |
a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed > 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No breakthrough IFD | Breakthrough IFD | |
| Caspofungin Arm | 133 | 16 |
| Micafungin Arm | 153 | 21 |
Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy. (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Caspofungin Arm | 122 | 27 |
| Micafungin Arm | 141 | 33 |
Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No ADE | ADE which caused EC therapy discontinuation | |
| Caspofungin Arm | 146 | 3 |
| Micafungin Arm | 172 | 2 |
aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 5x the upper limit of normal (ULN) or total bilirubin > 3x the upper limit of normal (ULN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No LFT elevations | AST > 5x upper limit of normal | ALT > 5x upper limit of normal | Total Bilirubin >3x upper limit of normal | |
| Caspofungin Arm | 110 | 14 | 10 | 15 |
| Micafungin Arm | 132 | 15 | 9 | 18 |
We assessed all patients in the study cohort who dischaged from the hospital alive (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Alive at hospital discharge | Died before hospitial discharge | |
| Caspofungin Arm | 137 | 12 |
| Micafungin Arm | 161 | 13 |
The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Adverse Event requiring EC discontinuation | Rash | Liver function Test (LFT) increase | Anaphylaxis | |
| Caspofungin Arm | 146 | 2 | 0 | 1 |
| Micafungin Arm | 172 | 1 | 1 | 0 |
Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Baseline IFD | Successfully treated baseline IFD | Unsuccessfully treated baseline IFD | |
| Caspofungin Arm | 146 | 2 | 1 |
| Micafungin Arm | 168 | 4 | 2 |
4 reviews available for fluconazole and Fever
| Article | Year |
|---|---|
[Fungal infections in oncohematology: the role of prophylaxis].
Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses | 2010 |
[Side effects of systemic antimycotics].
Topics: Amphotericin B; Antifungal Agents; Chills; Fever; Fluconazole; Humans; Itraconazole; Meta-Analysis a | 2003 |
[Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment].
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argenti | 2004 |
Empirical antifungal therapy in treating febrile neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Fe | 2004 |
10 trials available for fluconazole and Fever
| Article | Year |
|---|---|
Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemo | 2004 |
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
Topics: Adult; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Bacteremia; Candidi | 1995 |
Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study.
Topics: Adult; Amphotericin B; Aspergillosis, Allergic Bronchopulmonary; Bone Marrow Transplantation; Female | 1995 |
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive | 1994 |
Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amphotericin B; Antifungal Agents; Child; Child, Preschool | 1996 |
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Female; Fever; Fluconazole; Humans; Male; Midd | 1998 |
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Chemical and Drug Induc | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Ther | 2002 |
Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Bacterial Infections; Candidiasis; Child; Child, P | 1990 |
24 other studies available for fluconazole and Fever
| Article | Year |
|---|---|
(Ig)Easy diagnosis of disseminated coccidioidomycosis.
Topics: Coccidioidomycosis; Fever; Fluconazole; Humans; Male; Osteomyelitis; Tomography, X-Ray Computed | 2022 |
Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
Topics: Adult; Aged; Candida; Candidemia; Candidiasis; Female; Fever; Fluconazole; Humans; Liver; Male; Midd | 2017 |
[Case 136th--intermittent fever for over 20 days and coughing for 2 days].
Topics: Amphotericin B; Antifungal Agents; Biomarkers; Child; Cough; Cryptococcosis; Fever; Fluconazole; Hum | 2014 |
Beyond the superficial: Coccidioides immitis fungaemia in a man with fever, fatigue and skin nodules: a case of an emerging and evolving pathogen.
Topics: Antifungal Agents; Coccidioidomycosis; Communicable Diseases, Emerging; Diagnosis, Differential; Fat | 2014 |
Subcorneal pustular dermatosis associated with Coccidioides immitis.
Topics: Adolescent; Antifungal Agents; Back Pain; California; Coccidioides; Coccidioidomycosis; Delayed Diag | 2015 |
Coccidioidomycosis in infants: A retrospective case series.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Coccidioidomycosis; Cough; Diagnosis, Differential; | 2016 |
Double-blind active-control trials: beware the comparator you keep.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Double-Blind Method; Echinocandins; Fev | 2008 |
Recurrent Saccharomyces cerevisiae fungemia in an otherwise healthy patient.
Topics: Abdominal Pain; Adult; Amphotericin B; Antifungal Agents; Chills; Diagnosis, Differential; Female; F | 2011 |
68-year-old man with neutropenic fever and upper extremity hematoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherap | 2012 |
Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract.
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Eucalyptus; Fever; Fluconazole; Headache | 2002 |
Use of antifungal agents in febrile patients nonresponsive to antibacterial treatment: the current status in surgical and critical care patients in Japan.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Critical Care; Female; Fever; Fluconazole; Hu | 2002 |
[Treatment approach for fungal infections in critically ill patients admitted to intensive care units: results of a multicenter survey].
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Case Management; Consensus Development Conferences a | 2003 |
Tuboovarian abscess caused by Candida glabrata in a febrile neutropenic patient.
Topics: Abscess; Adult; Amphotericin B; Antifungal Agents; Antimetabolites, Antineoplastic; Candida glabrata | 2003 |
Coccidioidomycosis diagnosed in South Carolina.
Topics: Adult; Antifungal Agents; Coccidioides; Coccidioidomycosis; Cough; Diagnosis, Differential; Endemic | 2005 |
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis; Cohort Studies; Female; Fever; Fluconazole; | 2006 |
An unusual case of stroke and fevers in a traveler returning from Arizona.
Topics: Aged; Antifungal Agents; Arizona; Cerebral Infarction; Coccidiosis; Female; Fever; Fluconazole; Huma | 2008 |
Risk factors for hepatosplenic abscesses in patients with acute leukemia receiving empiric azole treatment.
Topics: Abscess; Acute Disease; Adolescent; Adult; Aged; Candidiasis; Female; Fever; Fluconazole; Humans; Le | 1994 |
Notable clinical changes of hepatosplenic abscesses in febrile neutropenic patients receiving empiric antifungal treatment with azoles.
Topics: Abscess; Antifungal Agents; Candidiasis; Fever; Fluconazole; Humans; Leukemia; Liver Abscess; Lympho | 1994 |
Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis; Cytosine; Eto | 1993 |
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antifungal Agents; Bone Marrow Transplantation; Fema | 1999 |
Cryptococcal meningitis in non-HIV-infected patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; C | 2000 |
Management of persistent fever in the neutropenic patient.
Topics: Amphotericin B; Antifungal Agents; Fever; Fluconazole; Humans; Mycoses; Neutropenia | 2000 |
Empirical antifungal therapy for persistent fever in patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillus; Deoxycholic Acid; Drug Combinations; Fever; Fluconaz | 2001 |
[Clinical efficacy of fluconazole in the patient with pulmonary mycosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antifungal Agents; Aspergillosis; Cr | 1989 |